A Targeted Nanotoxin Inhibits Colorectal Cancer Growth Through Local Tumor Pyroptosis and Eosinophil Infiltration and Degranulation
Por:
Carrasco-Díaz, LM, Gallardo, A, Voltà-Durán, E, Virgili, AC, Paez, D, Villaverde, A, Vazquez, E, Alamo, P, Unzueta, U, Casanova, I, Mangues, R and Alba-Castellon, L
Publicada:
1 ene 2025
Ahead of Print:
26 feb 2025
Resumen:
Background: Colorectal cancer (CRC) has traditionally been treated with genotoxic chemotherapy to activate pro-apoptotic proteins to induce anticancer effects. However, cancer cells develop resistance to apoptosis, which leads to recurrence and poor prognosis. Moreover, this kind of therapy has been shown to be highly toxic to healthy tissues and, therefore, to patients. To overcome this issue, we developed a self-assembly tumor-targeted nanoparticle, T22-DITOX-H6, that incorporates the T22 peptide (a CXCR4 ligand) to selectively target cells overexpressing CXCR4, fused to the catalytic domain of diphtheria toxin, that exhibits a potent cytotoxic effect on these CXCR4+ cancer cells that exhibits potent cytotoxic effects on CXCR4-overexpressing cancer cells through the activation of pyroptosis, an immunogenic type of cell death. Methods: Colorectal CXCR4-expressing tumor cells (CT26-CXCR4+) were implanted subcutaneously into immunocompetent mice to study the effects of T22-DITOX-H6 treatment on tumor growth, cell death and innate immune cell recruitment to the tumor. Results: Here, we demonstrated that the T22-DITOX-H6 nanoparticle selectively activated pyroptosis, an immunogenic cell death that differs from apoptosis, leading to cell death in CXCR4-expressing cells, without affecting the viability of CXCR4-lacking cells. In addition, the nanoparticle administered to tumor-bearing mice induced a local antitumor effect due to the selective activation of pyroptosis in CXCR4+ targeted cancer cells. Biochemical analysis of plasma and histological analysis of non-tumor tissues revealed no differences between the groups. Remarkably, pyroptosis activation stimulates eosinophil infiltration into the tumor microenvironment, an effect recently reported to have an anti-tumorigenic function. Conclusion: These results highlight the dual role of CXCR4-targeted cytotoxic nanoparticle in eliminating cancer cells and boosting the self-immune response without compromising healthy organs.
Filiaciones:
Carrasco-Díaz, LM:
Inst Recerca St Pau IR St PAU, Onco Hematol Dis Dept, Barcelona, Spain
Josep Carreras Leukaemia Res Inst IJC St Pau, Myeloid Neoplasms Program, Barcelona, Spain
CIBER Bioingn Biomat & Nanomed CIBER BBN, Madrid, Spain
Gallardo, A:
Hosp Santa Creu i St Pau, Dept Pathol, Barcelona, Spain
Voltà-Durán, E:
CIBER Bioingn Biomat & Nanomed CIBER BBN, Madrid, Spain
Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Bellaterra, Spain
Univ Autonoma Barcelona, Dept Genet & Microbiol, Bellaterra, Spain
Virgili, AC:
Inst Recerca St Pau IR St PAU, Onco Hematol Dis Dept, Barcelona, Spain
Hosp Santa Creu I St Pau, Dept Med Oncol, Barcelona, Spain
Paez, D:
Hosp Santa Creu I St Pau, Dept Med Oncol, Barcelona, Spain
CIBER Enfermedades Raras CIBERER, Madrid, Spain
Villaverde, A:
CIBER Bioingn Biomat & Nanomed CIBER BBN, Madrid, Spain
Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Bellaterra, Spain
Univ Autonoma Barcelona, Dept Genet & Microbiol, Bellaterra, Spain
Vazquez, E:
CIBER Bioingn Biomat & Nanomed CIBER BBN, Madrid, Spain
Univ Autonoma Barcelona, Inst Biotecnol & Biomed, Bellaterra, Spain
Univ Autonoma Barcelona, Dept Genet & Microbiol, Bellaterra, Spain
Alamo, P:
Inst Recerca St Pau IR St PAU, Onco Hematol Dis Dept, Barcelona, Spain
Josep Carreras Leukaemia Res Inst IJC St Pau, Myeloid Neoplasms Program, Barcelona, Spain
CIBER Bioingn Biomat & Nanomed CIBER BBN, Madrid, Spain
Unzueta, U:
Inst Recerca St Pau IR St PAU, Onco Hematol Dis Dept, Barcelona, Spain
Josep Carreras Leukaemia Res Inst IJC St Pau, Myeloid Neoplasms Program, Barcelona, Spain
CIBER Bioingn Biomat & Nanomed CIBER BBN, Madrid, Spain
Univ Autonoma Barcelona, Dept Genet & Microbiol, Bellaterra, Spain
:
Inst Recerca St Pau IR St PAU, Onco Hematol Dis Dept, Barcelona, Spain
Josep Carreras Leukaemia Res Inst IJC St Pau, Myeloid Neoplasms Program, Barcelona, Spain
CIBER Bioingn Biomat & Nanomed CIBER BBN, Madrid, Spain
Mangues, R:
Inst Recerca St Pau IR St PAU, Onco Hematol Dis Dept, Barcelona, Spain
Josep Carreras Leukaemia Res Inst IJC St Pau, Myeloid Neoplasms Program, Barcelona, Spain
CIBER Bioingn Biomat & Nanomed CIBER BBN, Madrid, Spain
Alba-Castellon, L:
Inst Recerca St Pau IR St PAU, Onco Hematol Dis Dept, Barcelona, Spain
Josep Carreras Leukaemia Res Inst IJC St Pau, Myeloid Neoplasms Program, Barcelona, Spain
CIBER Bioingn Biomat & Nanomed CIBER BBN, Madrid, Spain
Green Submitted, gold
|